0.7447
전일 마감가:
$0.7283
열려 있는:
$0.7283
하루 거래량:
774.45K
Relative Volume:
0.42
시가총액:
$292.35M
수익:
$86.26M
순이익/손실:
$-50.08M
주가수익비율:
-3.0408
EPS:
-0.2449
순현금흐름:
$-94.48M
1주 성능:
+0.65%
1개월 성능:
+10.60%
6개월 성능:
-17.98%
1년 성능:
-41.82%
Standard Biotools Inc Stock (LAB) Company Profile
명칭
Standard Biotools Inc
전화
(650) 266-6000
주소
50 MILK STREET, BOSTON
Compare LAB vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
LAB
Standard Biotools Inc
|
0.7447 | 290.47M | 86.26M | -50.08M | -94.48M | -0.2449 |
|
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-27 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | 개시 | TD Cowen | Buy |
| 2024-04-04 | 개시 | Jefferies | Buy |
| 2023-07-12 | 개시 | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc 주식(LAB)의 최신 뉴스
Standard BioTools Inks New Agreement to Sell Mass Cytometry Business for $5.5M - genomeweb.com
Standard BioTools (LAB) Revises Mass Cytometry Sale Agreement Ah - GuruFocus
Standard BioTools switches Mass Cytometry buyer to Element for $5.5M - Investing.com
Form 4 Standard Biotools Inc For: 30 September By Investing.com - Investing.com Nigeria
Standard Biotools Provides Update On Sale Of Mass Cytometry Business - TradingView
Standard BioTools Reaches New Mass Cytometry Sale Agreement - TipRanks
Standard BioTools to Sell Mass Cytometry Business to Element Biosystems for $5.5 Million - TradingView
Standard BioTools Finalizes $5.5M Mass Cytometry Business Sale to Element Biosystems - kalkinemedia.com
Standard BioTools Provides Update on Sale of Mass Cytometry Business - GlobeNewswire
Standard BioTools (LAB) Short Interest & Short Float | Updated Sep 2026 $LAB - MarketBeat
Standard BioTools Inc.Common Stock (Nasdaq:LAB) Detailed Stock Data - The Chronicle-Journal
Treeline deal leaves Standard BioTools (NASDAQ: LAB) investors with a minority stake - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—IRDM, VRME, VAL and LAB - GlobeNewswire Inc.
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB - Lelezard
Standard BioTools And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Standard BioTools (LAB) Slips 1.24% to $0.65 as Tight Trading Range Takes ShapeAscending Triangle - dars.gov.et
Standard Biotools Inc (LAB) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Standard BioTools (LAB) CEO uses 97K shares to pay taxes - Stock Titan
Standard (LAB) Session: Moves 0.73% Up to $0.65; Next Session: the Near-Term Reference Band Stretches From $0.62 to $0.68 under the Current SnapshotSentiment Shift - vinanet.vn
Enterprise value to EBIT forward of Standard BioTools Inc. – BX:FLB - TradingView
Long Focus Capital Management, LLC Adds to Standard BioTools Inc - GuruFocus
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Standard BioTools (LAB) Slides 4.99% to $0.71 as Selling Pressure PersistsFactor Valuation - vinanet.vn
Standard BioTools Inc (LAB) Fundamental & Financial Data - Stocktwits
Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing - Stock Titan
Standard BioTools Inc.: Target Price Consensus and Analysts Recommendations | LAB | US34385P1084 - marketscreener.com
Standard BioTools Inc (LAB) sentiment score, message volume, participation score and buzz level - Stocktwits
LAB: Standard BioTools Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake - Stock Titan
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LAB Q2 2026 Earnings: Deep EPS Miss Reveals Mounting Profitability PressuresPost-Announcement Reaction - dars.gov.et
Standard BioTools Inc (LAB) Stock News Today - TradingKey
Is Standard BioTools Inc (LAB) Overvalued After Q2 Loss? EPS: -$0.21, Revenue: $20.1M -- GF Score: 33/100 - GuruFocus
Standard BioTools Inc. (LAB) Stock Report: Evaluating a Potential 93% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Standard BioTools (LAB) Holds Steady at $0.80: Consolidation or Pivot Point Ahead?Quality ETF - dars.gov.et
Standard BioTools Reports Second Quarter 2026 Financial Results - The Manila Times
BlackRock, Inc. Reduces Standard BioTools Inc (LAB) Stake -- Sha - GuruFocus
Standard BioTools Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Standard BioTools (NASDAQ:LAB) Issues Earnings Results - MarketBeat
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss - TradingKey
Standard BioTools Q2 revenue falls on consumables weakness - TradingView
STANDARD BIOTOOLS ($LAB) Releases Q2 2026 Earnings - Quiver Quantitative
STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary - TradingView
Standard BioTools: Q2 Earnings Snapshot - barchart.com
Standard BioTools (NASDAQ: LAB) Q2 revenue $20.1M as merger advances - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-Standard BioTools Q2 EPS USD -0.07 - TradingView
Standard Biotools Inc. Withdraws Earnings Guidance for the Full Year 2026 - marketscreener.com
Price to sales forward of Standard BioTools Inc. – BX:FLB - TradingView
Standard BioTools (LAB) CEO has 362,625 shares withheld for taxes - stocktitan.net
Standard BioTools Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Standard Biotools Inc (LAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Standard Biotools Inc 주식 (LAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kim Hanjoon Alex | Chief Financial Officer |
Apr 06 '26 |
Option Exercise |
0.00 |
70,183 |
0 |
2,800,702 |
| Casdin Partners Master Fund, L | Director |
Dec 04 '25 |
Buy |
1.45 |
150,000 |
217,020 |
72,100,000 |
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 13 '25 |
Buy |
1.20 |
450,000 |
541,395 |
62,500,000 |
자본화:
|
볼륨(24시간):